Drug therapy in advanced cardiac life support

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Drug therapy during advanced cardiac life support for cardiac resuscitation continues to evolve, with new experimental and clinical data appearing each year. During the last year, important work has come forth in the following areas: optimal vaso-constrictive agents for improving coronary perfusion pressure during cardiopulmonary resuscitation; antiarrhythmic drug use for refractory ventricular fibrillation during ongoing cardiopulmonary resuscitation; and treatment of postresuscitation myocardial dysfunction. Much of the previous practice of drug therapy during cardiopulmonary resuscitation was based on anecdotal or consensus opinion. Careful prospective evaluation of drug therapy in both experimental and clinical settings is sorely needed. Such data have appeared recently for the use of vasopressin, amiodarone, and dobutamine during and after resuscitation.

Original languageEnglish (US)
Pages (from-to)161-164
Number of pages4
JournalCurrent Opinion in Critical Care
Volume4
Issue number3
StatePublished - 1998

Fingerprint

Advanced Cardiac Life Support
Cardiopulmonary Resuscitation
Drug Therapy
Resuscitation
Dobutamine
Amiodarone
Anti-Arrhythmia Agents
Ventricular Fibrillation
Vasopressins
Perfusion
Pressure
Therapeutics

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Drug therapy in advanced cardiac life support. / Kern, Karl B.

In: Current Opinion in Critical Care, Vol. 4, No. 3, 1998, p. 161-164.

Research output: Contribution to journalArticle

@article{cd111e487e0c4d4aad08bbbc18d092c9,
title = "Drug therapy in advanced cardiac life support",
abstract = "Drug therapy during advanced cardiac life support for cardiac resuscitation continues to evolve, with new experimental and clinical data appearing each year. During the last year, important work has come forth in the following areas: optimal vaso-constrictive agents for improving coronary perfusion pressure during cardiopulmonary resuscitation; antiarrhythmic drug use for refractory ventricular fibrillation during ongoing cardiopulmonary resuscitation; and treatment of postresuscitation myocardial dysfunction. Much of the previous practice of drug therapy during cardiopulmonary resuscitation was based on anecdotal or consensus opinion. Careful prospective evaluation of drug therapy in both experimental and clinical settings is sorely needed. Such data have appeared recently for the use of vasopressin, amiodarone, and dobutamine during and after resuscitation.",
author = "Kern, {Karl B}",
year = "1998",
language = "English (US)",
volume = "4",
pages = "161--164",
journal = "Current Opinion in Critical Care",
issn = "1070-5295",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Drug therapy in advanced cardiac life support

AU - Kern, Karl B

PY - 1998

Y1 - 1998

N2 - Drug therapy during advanced cardiac life support for cardiac resuscitation continues to evolve, with new experimental and clinical data appearing each year. During the last year, important work has come forth in the following areas: optimal vaso-constrictive agents for improving coronary perfusion pressure during cardiopulmonary resuscitation; antiarrhythmic drug use for refractory ventricular fibrillation during ongoing cardiopulmonary resuscitation; and treatment of postresuscitation myocardial dysfunction. Much of the previous practice of drug therapy during cardiopulmonary resuscitation was based on anecdotal or consensus opinion. Careful prospective evaluation of drug therapy in both experimental and clinical settings is sorely needed. Such data have appeared recently for the use of vasopressin, amiodarone, and dobutamine during and after resuscitation.

AB - Drug therapy during advanced cardiac life support for cardiac resuscitation continues to evolve, with new experimental and clinical data appearing each year. During the last year, important work has come forth in the following areas: optimal vaso-constrictive agents for improving coronary perfusion pressure during cardiopulmonary resuscitation; antiarrhythmic drug use for refractory ventricular fibrillation during ongoing cardiopulmonary resuscitation; and treatment of postresuscitation myocardial dysfunction. Much of the previous practice of drug therapy during cardiopulmonary resuscitation was based on anecdotal or consensus opinion. Careful prospective evaluation of drug therapy in both experimental and clinical settings is sorely needed. Such data have appeared recently for the use of vasopressin, amiodarone, and dobutamine during and after resuscitation.

UR - http://www.scopus.com/inward/record.url?scp=0039413678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0039413678&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0039413678

VL - 4

SP - 161

EP - 164

JO - Current Opinion in Critical Care

JF - Current Opinion in Critical Care

SN - 1070-5295

IS - 3

ER -